Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...

"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next ...

Indian drug companies are preparing to launch low-cost versions of Novo Nordisk’s Wegovy and Ozempic as patents expire in 2026, making weight-loss and diabetes treatment more affordable worldwide.

Telehealth firm 9amHealth has partnered with billionaire entrepreneur Mark Cuban's Cost Plus Drug Company to offer U.S.

In the aftermath of several deals with smaller biotechs made in the 13 months in the cardiometabolic space, Novo Nordisk has ...

Novo Holdings today released its Asia Investments Year in Review 2024, highlighting a year of strategic growth and ...

Novo Nordisk (NVO) is a healthcare company that discovers, develops, and markets medical products. The company operates in ...

A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...

Indian pharmaceutical companies are preparing to flood the market with generic versions of Novo Nordisk’s semaglutide—sold ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity ...

Indian pharmaceutical companies are gearing up to launch cost-effective versions of the weight-loss and diabetes drug, semaglutide, post patent expiry in 2026.